These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10230676)

  • 1. Molecular genetics of prostate cancer.
    Visakorpi T
    Ann Chir Gynaecol; 1999; 88(1):11-6. PubMed ID: 10230676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetics of prostate cancer.
    Nupponen NN; Visakorpi T
    Microsc Res Tech; 2000 Dec; 51(5):456-63. PubMed ID: 11074616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.
    Visakorpi T; Kallioniemi AH; Syvänen AC; Hyytinen ER; Karhu R; Tammela T; Isola JJ; Kallioniemi OP
    Cancer Res; 1995 Jan; 55(2):342-7. PubMed ID: 7529134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
    Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
    Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
    Laitinen S; Karhu R; Sawyers CL; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2002 Sep; 35(1):66-73. PubMed ID: 12203791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
    Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J
    Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
    El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
    Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetics of prostate cancer].
    Thomas F; Jaïs P; Cohen-Akenine A
    Bull Cancer; 2001 Mar; 88(3):287-94. PubMed ID: 11313206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries.
    Matsuda K; Matsuyama H; Hara T; Yoshihiro S; Oga A; Kawauchi S; Furuya T; Izumi H; Naito K; Sasaki K
    Cancer Genet Cytogenet; 2004 Jul; 152(2):119-23. PubMed ID: 15262429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of proximal 6q deletions in prostate cancer.
    Cooney KA; Wetzel JC; Consolino CM; Wojno KJ
    Cancer Res; 1996 Sep; 56(18):4150-3. PubMed ID: 8797584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular pathology of prostate carcinoma. Academic playground or guide for diagnosis and therapy planning?].
    Bubendorf L
    Verh Dtsch Ges Pathol; 2004; 88():158-64. PubMed ID: 16892547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology of progression of prostate cancer.
    Nupponen N; Visakorpi T
    Eur Urol; 1999; 35(5-6):351-4. PubMed ID: 10325488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines.
    Pan Y; Lui WO; Nupponen N; Larsson C; Isola J; Visakorpi T; Bergerheim US; Kytölä S
    Genes Chromosomes Cancer; 2001 Feb; 30(2):187-95. PubMed ID: 11135436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal changes during development and progression of prostate adenocarcinomas.
    Zitzelsberger H; Engert D; Walch A; Kulka U; Aubele M; Höfler H; Bauchinger M; Werner M
    Br J Cancer; 2001 Jan; 84(2):202-8. PubMed ID: 11161378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical dissection of genetic pathways involved in prostate carcinogenesis.
    Ribeiro FR; Diep CB; Jerónimo C; Henrique R; Lopes C; Eknaes M; Lingjaerde OC; Lothe RA; Teixeira MR
    Genes Chromosomes Cancer; 2006 Feb; 45(2):154-63. PubMed ID: 16235241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray.
    Jiang M; Li M; Fu X; Huang Y; Qian H; Sun R; Mao Y; Xie Y; Li Y
    Prostate; 2008 Oct; 68(14):1496-509. PubMed ID: 18366025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Debruyne FM; Collins VP; van Dekken H; Jenkins RB; Klocker H; Schalken JA; Sesterhenn IA
    Scand J Urol Nephrol Suppl; 1994; 162():65-71; discussion 115-27. PubMed ID: 7817161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal aberrations in prostate cancer.
    Saramaki O; Visakorpi T
    Front Biosci; 2007 May; 12():3287-301. PubMed ID: 17485299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal basis of adenocarcinoma of the prostate.
    Verma RS; Manikal M; Conte RA; Godec CJ
    Cancer Invest; 1999; 17(6):441-7. PubMed ID: 10434955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma.
    Schulz WA; Elo JP; Florl AR; Pennanen S; Santourlidis S; Engers R; Buchardt M; Seifert HH; Visakorpi T
    Genes Chromosomes Cancer; 2002 Sep; 35(1):58-65. PubMed ID: 12203790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.